

PHARMACEUTICAL 2023

Disc Medicine Inc. Rank 69 of 446







RealRate

PHARMACEUTICAL 2023

## Disc Medicine Inc. Rank 69 of 446

The relative strengths and weaknesses of Disc Medicine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Disc Medicine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Disc Medicine Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 186% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	198,491
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,578
Liabilities, Non-Current	1,027
Other Assets	1,546
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	648
Other Revenues	0
Property and Equipment	168
Research and Development	33,437
Selling, General and Administrative Expense	14,038

Output Variable	Value in 1000 USD
Assets	200,205
Liabilities	23,605
Expenses	47,475
Revenues	0
Stockholders Equity	176,600
Net Income	-46,827
Comprehensive Net Income	-46,827
Economic Capital Ratio	230%

